I hesitated while pasting together this Bio-Twitter Year in Review because... Does anyone really want to remember what happened in 2016?
Don’t all raise your hands at once; 2016 was a lousy year for biotech investors. It started bad, got worse, perked up, got worse again, rebounded just a little, looked like it was normalizing then tanked -- again.
Brutal.
